Long-Term Outcomes of Unprotected Left Main Percutaneous Coronary Intervention in Centers Without Onsite Cardiac Surgery.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 04 2022
Historique:
received: 29 09 2021
revised: 10 12 2021
accepted: 20 12 2021
pubmed: 5 2 2022
medline: 16 4 2022
entrez: 4 2 2022
Statut: ppublish

Résumé

Unprotected left main (LM) percutaneous coronary intervention (PCI) at centers without onsite cardiac surgery remains controversial. We aimed to evaluate the effect of onsite cardiac surgery on short-term and long-term outcomes in patients who had unprotected LM PCI. We analyzed Victorian Cardiac Outcomes Registry data on consecutive patients who had unprotected LM PCI at cardiac surgical centers (SCs) and non-SCs (NSCs) between January 2014 to December 2018. Compared with the SC group (n = 594, 81%), the NSC group (n = 136) were younger (69 vs 72 years) and presented with more ST-elevation myocardial infarction (35% vs 16%) and cardiogenic shock (25% vs 15%), with higher rates of preprocedural intubation (17% vs 11%) and mechanical circulatory support (20% vs 9.3%), all p <0.01. Unadjusted in-hospital mortality (23% vs 11.4%), and 30-day major adverse cardiac events (composite of mortality, myocardial infarction, stent thrombosis, or unplanned revascularization) (26% vs 16%) were higher in NSC patients, all p <0.01. However, following multivariable adjustment, SC was neither a predictor of in-hospital mortality (odds ratio 0.68, 95% confidence interval [CI] 0.32 to 1.43, p = 0.31), 30-day mortality (odds ratio 0.70, 95% CI 0.33 to 1.48, p = 0.35) nor long-term survival at 60 months (hazard ratio 0.88, 95% CI 0.62 to 1.27, p = 0.51). Propensity score analysis confirmed the neutral effect of onsite cardiac surgery on long-term survival (hazard ratio 0.99, 95% CI 0.66 to 1.50, p = 0.97). In conclusion, patients who underwent unprotected LM PCI at NSCs presented with greater acuity of illness. Despite this, the availability of onsite cardiac surgical support was not associated with in-hospital, 30-day, or long-term outcomes underscoring the safety of LM PCI in NSCs.

Identifiants

pubmed: 35115134
pii: S0002-9149(21)01266-2
doi: 10.1016/j.amjcard.2021.12.051
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

39-46

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures The authors have no conflicts of interest to declare.

Auteurs

Laura Hanson (L)

Department of Cardiology, Western Health, Victoria, Australia; Department of Cardiology, Alfred Health, Victoria, Australia.

Sara Vogrin (S)

Department of Medicine, University of Melbourne, Victoria, Australia.

Samer Noaman (S)

Department of Cardiology, Western Health, Victoria, Australia; Department of Cardiology, Alfred Health, Victoria, Australia.

Diem Dinh (D)

Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia.

Wayne Zheng (W)

Department of Cardiology, Western Health, Victoria, Australia; Department of Cardiology, Alfred Health, Victoria, Australia.

Jeffrey Lefkovits (J)

Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia.

Angela Brennan (A)

Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia.

Christopher Reid (C)

Department of Cardiology, Western Health, Victoria, Australia.

Dion Stub (D)

Department of Cardiology, Western Health, Victoria, Australia; Department of Cardiology, Alfred Health, Victoria, Australia; The Baker Heart and Diabetes Institute, Victoria, Australia.

Stephen J Duffy (SJ)

Department of Cardiology, Alfred Health, Victoria, Australia; The Baker Heart and Diabetes Institute, Victoria, Australia.

Jamie Layland (J)

Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia.

Melanie Freeman (M)

Centre of Cardiovascular Research & Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia; Epworth Cardiac Services Clinical Institute, Victoria, Australia.

William van Gaal (W)

Department of Cardiology, Northern Health, Victoria, Australia.

Nicholas Cox (N)

Department of Cardiology, Western Health, Victoria, Australia; Department of Medicine, University of Melbourne, Victoria, Australia.

William Chan (W)

Department of Cardiology, Western Health, Victoria, Australia; Department of Cardiology, Alfred Health, Victoria, Australia; Department of Medicine, University of Melbourne, Victoria, Australia; The Baker Heart and Diabetes Institute, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH